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Osteosarcoma (OS) is the most commonly diagnosed
primary malignancy of bone, particularly among chil-
dren and adolescents.1 During the last 25 years, remark-
able progress has been made in the treatment of OS.
The combination of chemotherapy and limb-sparing
surgery for OS patients has led to an overall 5-year
survival rate of around 70% and limb preservation rate
of > 90% for localized disease.2 However, 30–50% of
patients with initially localized disease subsequently
developed recurrence, and 20–30% of newly diagnosed
cases presented with metastatic disease. In cases of
recurrent or metastatic tumor where complete resection
is not possible, the 3-year progression-free survival is
0% due to failure of rescue chemotherapy.3 It is there-
fore crucial to identify the prognostic factors in patients
with OS to predict treatment response, recurrence and
survival.
Several prognostic factors have been identified by
previous studies, including age, tumor size, histological
type, and site. However, reporting of such associations
across different studies has often been inconsistent.
Recently, there was an international collaboration of
10 teams of investigators (including 2,680 patients),
and the prognostic significance of traditional clinical
predictors in OS was evaluated. In multivariate models,
patients with poor histologic response to chemotherapy,
having metastatic disease at diagnosis, or on chemother-
apy regimens not including anthracycline, had higher
chance of death, distant metastasis and local recurrence.
Amputation instead of limb salvage/wide resection
was predictive of a higher risk of mortality and distant
metastasis. Development of local recurrence when the
patient was first seen was an independent prognostic
factor associated with death and local recurrence. In
this study, the prognostic influence of age at the start
of the follow-up period was also investigated. Older
age was associated with poor survival (7% relative risk
increase per decade) and increased risk of local recur-
rence.4 This is consistent with previous reports. One
possible explanation is that there is a high percentage
of OS with Paget’s disease and OS as a second or later
cancer among the elderly. These so-called secondary
OS are considered chemoresistant and are more diffi-
cult to treat.1
However, this study did not address the issue of
whether or not patients of younger age (< 10 years old)
may have worse outcome. In this issue of the Journal
of the Chinese Medical Association, Hsieh et al report 
a paper discussing the prognostic influence of younger
age on OS.5 As the authors mention in their paper,
currently available studies have conflicting results. Kim
et al developed a prognostic nomogram for predicting
the 5-year probability of developing metastasis after
neoadjuvant chemotherapy and definitive surgery based
on 365 OS patients treated at a single institution.6
Multivariate Cox model disclosed that patient age at
diagnosis, tumor size, humeral location, and tumor
necrosis rate after chemotherapy were correlated with
metastasis-free survival. In the analysis of age, they
found a poor outcome in both older patients (age >
40 years) and a subgroup of patients aged 12–15 years,
which represents the period of undergoing growth
spurt. Patients aged < 12 years actually did better than
these 2 groups.6 This is consistent with previous stud-
ies. It seems that the prognostic influence of age may
reflect the underlying biology of cancer development
(growth spurt).
If that is the case, we can look at this issue from a
tumor biology viewpoint. Several genetic mechanisms
have been associated with OS tumorigenesis. These
include cell genomic changes associated with cycle alter-
ations, such as TP53, RB1, and MDM2, disturbance
of cell senescence pathways resulting from telomere
dysfunction, and alterations in cell death/cytokine
pathways resulting from FAS dysregulation.7 Retino-
blastoma survivors have an increased incidence of 
second malignancies, the majority of which are OS.8
Loss of heterozygosity of RB1 has been associated with
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poor event-free survival in OS patients,9 and was asso-
ciated with a significantly younger age at diagnosis.8
However, most of these studies have limited case num-
ber, and further confirmation in larger scale surveys is
warranted.
Hsieh et al found that patients aged ≤ 10 years had
a higher chance of poor response to chemotherapy.5
The classic example of chemoresistance is multidrug
resistance (MDR) mediated by the MDR1 gene. The
protein product of MDR1, P-glycoprotein (Pgp), is 
a plasma membrane protein that acts as an adenosine
triphosphate-dependent efflux pump responsible for
removing cytotoxic molecules, including chemother-
apeutic agents, from cells. High levels of MDR1 gene
expression has been considered to be a prime mecha-
nism of drug resistance in OS. However, in a meta-
analysis of 14 studies (including 631 patients) that
evaluated the correlation between Pgp and histologic
response to chemotherapy and clinical disease progres-
sion (death, metastasis or recurrence), Pgp was not
found to have discriminating ability to identify poor
responders versus good responders to chemotherapy,
but instead had strong associations with the risk of
disease progression.10 So the expression of Pgp may be
considered a prognostic factor. Serra et al found that
patients younger than 12 years had a higher chance of
relapse and shorter event-free survival, and there was
a clear trend toward a higher frequency of Pgp expres-
sion in this group of patients.11 So overexpression of
Pgp may explain the relatively poor outcome in some
of the younger OS patients.
Other factors may influence the outcome in
younger patients, such as delayed diagnosis due to
unawareness of the symptoms, and higher chance of
chemotherapy-induced toxicity leading to intolerance
to treatment.12 However, these factors need further
clarification. In summary, age is considered a prognos-
tic factor in OS. Older age (> 40 years) is associated
with poor survival and increased risk of recurrence,
possibly attributed to the relatively chemoresistant
nature of secondary cancer. However, the prognostic
significance of younger age (< 10 years or preadoles-
cent) remains controversial. An international collabo-
rative study is necessary to answer the following
questions: (1) Do patients younger than 10 years actu-
ally do worse than older patients? (2) If the answer to
question 1 is affirmative, are there any biomarkers that
are associated with this poor outcome? (3) If such
markers can be identified, could these markers be used
as diagnostic or therapeutic targets? Through this joint
effort, hopefully we can further improve the care of
OS patients.
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